Nevro Corp (1N7.SG)
| Previous Close | 10.30 |
| Open | 10.70 |
| Bid | 9.40 x 200000 |
| Ask | 9.45 x 50000 |
| Day's Range | 10.70 - 10.70 |
| 52 Week Range | 9.65 - 26.40 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Nevro Reports First-Quarter 2024 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its first quarter 2024 financial results. The company also announced additional restructuring steps to advance its strategy and accelerate profitability, raised its adjusted EBITDA guidance and reaffirmed its revenue guidance for the full-year 2024, and announced that Christofer Christoforou has been promoted to the newly created Ch
- PR Newswire
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the first quarter of 2024 after the market closes on Tuesday, May 7, 2024. The company will also host a conference call beginning at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss its financial results.
- PR Newswire
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the U.S. Food and Drug Administration (FDA) cleared its sacroiliac joint fusion device, which will be marketed as Nevro1, without the need to include the screw ("NevroFix™").
